What question did this study set out to answer?

This research aims to compare the effects of prolonged dual antiplatelet therapy on clinical outcomes in patients with high residual inflammatory risk post-PCI.

June 27, 2026Journal of Inflammation ResearchOpen Access

Prolonged DAPT beyond 12 months linked to ~65% lower MACCE risk versus conventional therapy.

Q: What is the clinical evidence from this study?

Study design: Observational. Population: Coronary artery disease with high residual inflammatory risk post-PCI (n=3510). Intervention: Prolonged dual antiplatelet therapy (>12 months) vs. Conventional dual antiplatelet therapy (≤12 months). Primary outcome: Major adverse cardiac and cerebrovascular events (MACCE) at 3 years (adjusted HR 0.347, 95% CI 0.224-0.539, p=<0.001).

View Full Paper

Ask AI

Bookmark

Why the study?

Does prolonged dual antiplatelet therapy (>12 months) reduce ischemic events compared to conventional therapy (≤12 months) in post-PCI patients with high residual inflammatory risk?

Population

Post-percutaneous coronary intervention patients with high residual inflammatory risk enrolled at Fuwai…

Comparison

Prolonged dual antiplatelet therapy for > 12… vs Conventional dual antiplatelet therapy for ≤ 12…

Design

Cohort

Follow-up

3 years

Key result

Prolonged dual antiplatelet therapy beyond 12 months significantly reduced the 3-year risk of major adverse cardiac and cerebrovascular events compared to conventional therapy (1.5% vs. 4.2%; adjusted HR 0.347).

Authors

ZWZiyi Wang YSYanjun Song ZZZe Zheng

Discussion

Member takes

Overview

Prolonged DAPT was associated with fewer ischemic events without excess bleeding; leaves open whether randomized trials will confirm benefit post-stenting.

Key Points

This research aims to compare the effects of prolonged dual antiplatelet therapy on clinical outcomes in patients with high residual inflammatory risk post-PCI.
Prospective observational study at Fuwai Hospital.
Patients stratified into prolonged (> 12 months) and conventional (≤ 12 months) DAPT groups.
Primary outcome assessed was a composite of all-cause death, myocardial infarction, definite or probable stent thrombosis, or stroke at 3 years.
Prolonged DAPT showed a significantly lower risk of the primary outcome (1.5% vs. 4.2%; adjusted HR: 0.347, 95% CI: 0.224–0.539).
Net adverse clinical events were also lower with prolonged DAPT (1.4% vs. 4.1%; adjusted HR: 0.338, 95% CI: 0.216–0.53).
No significant difference in bleeding rates between DAPT groups (1.0% vs. 1.2%; adjusted HR: 0.793, 95% CI: 0.401–1.57).

Study Design

Type

Observational (n=3,510)

Multicenter

Structured PICO

Does prolonged dual antiplatelet therapy (>12 months) reduce ischemic events compared to conventional therapy (≤12 months) in post-PCI patients with high residual inflammatory risk?

Population

3,510 post-PCI patients with high residual inflammatory risk (hs-CRP ≥ 2 mg/L) who were event-free at 12 months, followed for 3 years.

Exposure

Prolonged dual antiplatelet therapy (aspirin + P2Y12 inhibitor) for > 12 months

Comparator

Conventional dual antiplatelet therapy (aspirin + P2Y12 inhibitor) for ≤ 12 months

Outcome

Composite endpoint of all-cause death, myocardial infarction, definite or probable stent thrombosis, or stroke at 3 yearscomposite

Main Result

Hazard Ratio: 0.347 (95% CI 0.224–0.539)

Absolute Event Rate: 1.5% vs 4.2%

p-value: p=<0.001

In post-PCI patients with high residual inflammatory risk, extending dual antiplatelet therapy beyond 12 months significantly reduces ischemic events without increasing clinically significant bleeding.

Limitations

Observational, non-randomized design precluding causal inferences and limited by selection bias
Unbalanced baseline characteristics between groups
Only clopidogrel and aspirin were used, limiting extrapolation to more potent P2Y12 inhibitors
Based on baseline hs-CRP levels without follow-up measurements
Lower-than-expected event rate constraining statistical power
Study population defined by PCI procedure rather than underlying clinical diagnosis

Cite This Study

Wang et al. (2026) conducted an observational in Coronary artery disease with high residual inflammatory risk post-PCI (n=3,510). Prolonged dual antiplatelet therapy (>12 months) vs. Conventional dual antiplatelet therapy (≤12 months) was evaluated on Major adverse cardiac and cerebrovascular events (MACCE) at 3 years (adjusted HR 0.347, 95% CI 0.224-0.539, p=<0.001). Prolonged dual antiplatelet therapy beyond 12 months significantly reduced the 3-year risk of major adverse cardiac and cerebrovascular events compared to conventional therapy (1.5% vs. 4.2%; adjusted HR 0.347).

synapsesocial.com/papers/6a3f97bb125782b61d865907 https://doi.org/10.2147/jir.s607214

View Full Paper

Ask AI

Bookmark

June 27, 2026Journal of Inflammation ResearchOpen Access

Prolonged DAPT beyond 12 months linked to ~65% lower MACCE risk versus conventional therapy.

View Full Paper

Ask AI

Bookmark

Why the study?

Does prolonged dual antiplatelet therapy (>12 months) reduce ischemic events compared to conventional therapy (≤12 months) in post-PCI patients with high residual inflammatory risk?

Population

Post-percutaneous coronary intervention patients with high residual inflammatory risk enrolled at Fuwai…

Comparison

Prolonged dual antiplatelet therapy for > 12… vs Conventional dual antiplatelet therapy for ≤ 12…

Design

Cohort

Follow-up

3 years

Key result

Authors

ZWZiyi Wang YSYanjun Song ZZZe Zheng

Discussion

Member takes

Overview

Prolonged DAPT was associated with fewer ischemic events without excess bleeding; leaves open whether randomized trials will confirm benefit post-stenting.

Key Points

This research aims to compare the effects of prolonged dual antiplatelet therapy on clinical outcomes in patients with high residual inflammatory risk post-PCI.
Prospective observational study at Fuwai Hospital.
Patients stratified into prolonged (> 12 months) and conventional (≤ 12 months) DAPT groups.
Primary outcome assessed was a composite of all-cause death, myocardial infarction, definite or probable stent thrombosis, or stroke at 3 years.
Prolonged DAPT showed a significantly lower risk of the primary outcome (1.5% vs. 4.2%; adjusted HR: 0.347, 95% CI: 0.224–0.539).
Net adverse clinical events were also lower with prolonged DAPT (1.4% vs. 4.1%; adjusted HR: 0.338, 95% CI: 0.216–0.53).
No significant difference in bleeding rates between DAPT groups (1.0% vs. 1.2%; adjusted HR: 0.793, 95% CI: 0.401–1.57).

Study Design

Type

Observational (n=3,510)

Multicenter

Structured PICO

Does prolonged dual antiplatelet therapy (>12 months) reduce ischemic events compared to conventional therapy (≤12 months) in post-PCI patients with high residual inflammatory risk?

Population

3,510 post-PCI patients with high residual inflammatory risk (hs-CRP ≥ 2 mg/L) who were event-free at 12 months, followed for 3 years.

Exposure

Prolonged dual antiplatelet therapy (aspirin + P2Y12 inhibitor) for > 12 months

Comparator

Conventional dual antiplatelet therapy (aspirin + P2Y12 inhibitor) for ≤ 12 months

Outcome

Composite endpoint of all-cause death, myocardial infarction, definite or probable stent thrombosis, or stroke at 3 yearscomposite

Main Result

Hazard Ratio: 0.347 (95% CI 0.224–0.539)

Absolute Event Rate: 1.5% vs 4.2%

p-value: p=<0.001

Limitations

Observational, non-randomized design precluding causal inferences and limited by selection bias
Unbalanced baseline characteristics between groups
Only clopidogrel and aspirin were used, limiting extrapolation to more potent P2Y12 inhibitors
Based on baseline hs-CRP levels without follow-up measurements
Lower-than-expected event rate constraining statistical power
Study population defined by PCI procedure rather than underlying clinical diagnosis

Cite This Study

synapsesocial.com/papers/6a3f97bb125782b61d865907 https://doi.org/10.2147/jir.s607214

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

View Full Paper

Ask AI

Bookmark